CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Health-care companies rose as investors bet on anti-obesity products. Omada Health shares jumped after the maker of digital products that help track diet and other diabetes factors made its ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...